Johnson & Johnson takes the 340B drug rebate fight to federal court

The latest stories trending on MedCity News.

Editor's Pick

Top Story Johnson & Johnson Takes the 340B Drug Rebate Fight to Federal Court Johnson & Johnson is suing the federal agencies overseeing the 340B program that makes discounted medicines more accessible to uninsured and underserved patients. J&J contends the Health Resources Services Administration can't legally oppose its plan to implement a new rebate plan for certain 340B drugs. Sponsored Biotech Showcase™: 17 years of innovation and opportunity Presented by Biotech Showcase™ & EBD Group Join Biotech Showcase, Jan 13-15, 2025—the premier conference for private, small-cap, seed, and techbio companies. Connect with key investors during the healthcare sector's most pivotal week. Learn more! Startups Take the Stage and Pitch Directly to Investors at INVEST 2025 If your startup is focused on any of these niches, apply to present your solution at the Pitch Perfect Competition in Chicago, April 29-30, 2025, during INVEST and speak directly to investors. Biopharma Startups focused on infectious diseases.  Devices & Diagnostics  Startups focused on diabetes.  Healthtech: Consumer/Employer Startups addressing care navigation and care coordination. Healthtech: Payer/Provider Startups addressing AI to boost workflow and efficiency. Deadline for applications is December 13th. Apply to Pitch at INVEST 2025 Now

Featured News

How One Optum Exec Is Handling the Influx of Digital Mental Health Solutions There has been a surge in digital mental health solutions, making it difficult to know which ones are effective. One Optum exec weighed in on how she's managing this challenge. High Labor Costs Continue to Plague Providers, Data Shows High labor costs remain an ongoing problem threatening providers' bottom lines, according to new data from Kaufman Hall. The research revealed that medical groups' median investment in each employed physician has reached more than $300,000 for the first time. The Rapid Growth of GLP-1s and Their Impact on Bariatric Surgery Bariatric surgery is still the gold standard for morbid obesity treatment, yet patients and medical professionals will likely seek less invasive weight loss drugs before considering bariatric surgery.  Trump, RFK Jr., and the Healthcare Bombshell No One Sees Coming The convergence of Trump's political capital, Kennedy's agricultural vision, and existing technological capabilities creates an unprecedented opportunity to restructure America's approach to health and disease prevention.

Resources

SPONSORED EMR Software Pricing Guide How do you know if you're spending too much or too little on EMR software? This guide from Software Advice breaks down upfront, subscription and hidden costs, plus answers other questions you've been wondering about. Download Free Guide Now

MedCity News • PO Box 901 • New York, NY unsubscribe